Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
USRE48960 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(1 year, 3 months from now) | |
US9447415 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(1 year, 3 months from now) | |
US10287586 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(6 years from now) | |
US9228187 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9758783 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(6 years from now) | |
US10781450 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Feb 25, 2028 |
New Chemical Entity Exclusivity (NCE) | Feb 25, 2026 |
Drugs and Companies using CASIMERSEN ingredient
NCE-1 date: 2025-02-25
Market Authorisation Date: 25 February, 2021
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping; Treatment of duchenne muscular dystrophy (dmd) in patients who have...
Dosage: SOLUTION;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10927129 | VIIV HLTHCARE | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
Apr, 2026
(2 years from now) | |
US8410103 | VIIV HLTHCARE | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
Apr, 2026
(2 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11224597 | VIIV HLTHCARE | Pharmaceutical compositions |
Sep, 2031
(7 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 21, 2026 |
Drugs and Companies using CABOTEGRAVIR ingredient
NCE-1 date: 2025-01-21
Market Authorisation Date: 20 December, 2021
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10584112 | COMMAVE THERAP | Methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(13 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9079928 | COMMAVE THERAP | Methylphenidate-oxoacid conjugates, processes of making and using the same |
Jul, 2032
(8 years from now) | |
US10759778 | COMMAVE THERAP | Methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(13 years from now) | |
US10584113 | COMMAVE THERAP | Methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(13 years from now) | |
US10858341 | COMMAVE THERAP | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(13 years from now) | |
US10954213 | COMMAVE THERAP | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 7, 2026 |
NCE-1 date: 2025-05-07
Market Authorisation Date: 07 May, 2021
Treatment: Treatment of attention-deficit hyperactivity disorder (adhd) with serdexmethylphenidate and dexmethylphenidate
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7132416 | ALBIREO | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia |
Sep, 2022
(1 year, 6 months ago) | |
US10975046 | ALBIREO | Crystal modifications of odevixibat |
Jun, 2039
(15 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10487111 | ALBIREO | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(7 years from now) | |
US10093697 | ALBIREO | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(7 years from now) | |
US11732006 | ALBIREO | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(7 years from now) | |
US10011633 | ALBIREO | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(7 years from now) | |
US10981952 | ALBIREO | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(7 years from now) | |
US9694018 | ALBIREO | IBAT inhibitors for the treatment of liver disease |
Nov, 2031
(7 years from now) | |
US11801226 | ALBIREO | Pharmaceutical formulation of odevixibat |
Jun, 2039
(15 years from now) | |
US11365182 | ALBIREO | Crystal modifications of odevixibat |
Jun, 2039
(15 years from now) | |
US11802115 | ALBIREO | Pharmaceutical formulation of odevixibat |
Jun, 2039
(15 years from now) | |
US11583539 | ALBIREO | Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors |
Nov, 2041
(17 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 20, 2026 |
Orphan Drug Exclusivity (ODE) | Jul 20, 2028 |
New Indication (I) | Jun 13, 2026 |
Drugs and Companies using ODEVIXIBAT ingredient
NCE-1 date: 2025-07-20
Market Authorisation Date: 20 July, 2021
Treatment: Method of reducing serum bile acids in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic); Method of treating pruritus in patients 3 months or older sufferi...
Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8080551 | VIIV HLTHCARE | HIV inhibiting pyrimidines derivatives |
Apr, 2023
(11 months ago) | |
US7125879 | VIIV HLTHCARE | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(1 year, 26 days from now) | |
US10927129 | VIIV HLTHCARE | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
Apr, 2026
(2 years from now) | |
US8410103 | VIIV HLTHCARE | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
Apr, 2026
(2 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11389447 | VIIV HLTHCARE | Aqueous suspensions of TMC278 |
Jun, 2027
(3 years from now) | |
US11224597 | VIIV HLTHCARE | Pharmaceutical compositions |
Sep, 2031
(7 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 21, 2026 |
New Patient Population (NPP) | Mar 29, 2025 |
New Dosing Schedule (D) | Jan 31, 2025 |
Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient
NCE-1 date: 2025-01-21
Market Authorisation Date: 21 January, 2021
Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg by monthly administration of rilpivirine suspension as part of combination therapy; Treatme...
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9957276 | G1 THERAP | CDK inhibitors |
Oct, 2031
(7 years from now) | |
US10189849 | G1 THERAP | CDK inhibitors |
Oct, 2031
(7 years from now) | |
US8598186 | G1 THERAP | CDK inhibitors |
Oct, 2031
(7 years from now) | |
US8598197 | G1 THERAP | CDK inhibitors |
Oct, 2031
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10927120 | G1 THERAP | CDK inhibitors |
Oct, 2031
(7 years from now) | |
US10189850 | G1 THERAP | CDK inhibitors |
Oct, 2031
(7 years from now) | |
US10966984 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(9 years from now) | |
US10085992 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(9 years from now) | |
US11040042 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(9 years from now) | |
US9487530 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(9 years from now) | |
US11717523 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(9 years from now) | |
US11529352 | G1 THERAP | Preservation of immune response during chemotherapy regimens |
Jul, 2039
(15 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 12, 2026 |
Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient
NCE-1 date: 2025-02-12
Market Authorisation Date: 12 February, 2021
Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen for extensive-stage small cell lung can...
Dosage: POWDER;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9333270 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(9 years from now) | |
US10881747 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(9 years from now) | |
US9789208 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(9 years from now) | |
US9341629 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(9 years from now) | |
US9061057 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(9 years from now) | |
US9254341 | ON TARGET LABS | Methods of manufacture of pteroyl-amino acid-fluorescent dyes |
Oct, 2033
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 29, 2026 |
New Indication (I) | Dec 16, 2025 |
Orphan Drug Exclusivity (ODE) | Nov 29, 2028 |
Drugs and Companies using PAFOLACIANINE SODIUM ingredient
NCE-1 date: 2025-11-29
Market Authorisation Date: 29 November, 2021
Treatment: Cytalux is an optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions
Dosage: SOLUTION;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9169307 | APELLIS PHARMS | Potent compstatin analogs |
Nov, 2027
(3 years from now) | |
US7989589 | APELLIS PHARMS | Compstatin analogs with improved activity |
Dec, 2027
(3 years from now) | |
US7888323 | APELLIS PHARMS | Potent compstatin analogs |
Dec, 2027
(3 years from now) | |
US11661441 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Jan, 2033
(8 years from now) | |
US10125171 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Aug, 2033
(9 years from now) | |
US11292815 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
US10035822 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
US10875893 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11040107 | APELLIS PHARMS | Dosing regimens and related compositions and methods |
Apr, 2038
(14 years from now) | |
US11844841 | APELLIS PHARMS | Dosing regimens and related compositions and methods |
Dec, 2038
(14 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 14, 2026 |
Orphan Drug Exclusivity (ODE) | May 14, 2028 |
M (M) | Feb 8, 2026 |
Drugs and Companies using PEGCETACOPLAN ingredient
NCE-1 date: 2025-05-14
Market Authorisation Date: 14 May, 2021
Treatment: Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of 1080 mg of pegcetacoplan; Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by ...
Dosage: SOLUTION;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9796712 | TAKEDA PHARMS USA | Heteroaryl compounds for kinase inhibition |
May, 2035
(11 years from now) | |
US10227342 | TAKEDA PHARMS USA | Heteroaryl compounds for kinase inhibition |
May, 2035
(11 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 15, 2026 |
Orphan Drug Exclusivity (ODE) | Sep 15, 2028 |
Drugs and Companies using MOBOCERTINIB SUCCINATE ingredient
NCE-1 date: 2025-09-15
Market Authorisation Date: 15 September, 2021
Treatment: Treatment of patients with non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 exon insertion mutations whose disease has progressed on or after platinum-based chem...
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6821987 | AVEO PHARMS | Quinoline derivatives and quinazoline derivatives having azolyl group |
Apr, 2024
(a month from now) | |
US7166722 | AVEO PHARMS | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form |
Nov, 2024
(7 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11504365 | AVEO PHARMS | NA |
Nov, 2039
(15 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 10, 2026 |
Drugs and Companies using TIVOZANIB HYDROCHLORIDE ingredient
NCE-1 date: 2025-03-10
Market Authorisation Date: 10 March, 2021
Treatment: Treatment of adults with moderate hepatic impairment and relapsed or refractory advanced renal cell carcinoma following two or more prior systemic anti-cancer therapies with 1mg tivozanib hcl orally f...
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8436180 | BAYER HLTHCARE | Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof |
Apr, 2029
(5 years from now) | |
USRE49826 | BAYER HLTHCARE | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient |
Jul, 2035
(11 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 9, 2026 |
M (M) | Sep 1, 2025 |
Drugs and Companies using FINERENONE ingredient
NCE-1 date: 2025-07-09
Market Authorisation Date: 09 July, 2021
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10017536 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(3 years from now) | |
US7727963 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(3 years from now) | |
US7713937 | CARA THERAP | Synthetic peptide amides and dimeric forms thereof |
Nov, 2027
(3 years from now) | |
US8536131 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(3 years from now) | |
US7402564 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(3 years from now) | |
US10793596 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9359399 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(3 years from now) | |
US8236766 | CARA THERAP | Uses of synthetic peptide amides |
Nov, 2027
(3 years from now) | |
US8486894 | CARA THERAP | Synthetic peptide amides and dimeric forms thereof |
Nov, 2027
(3 years from now) | |
US10138270 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(3 years from now) | |
US9334305 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(3 years from now) | |
US8217007 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Aug 23, 2026 |
Drugs and Companies using DIFELIKEFALIN ACETATE ingredient
NCE-1 date: 2025-08-23
Market Authorisation Date: 23 August, 2021
Treatment: Treatment of moderate-to-severe pruritus associated with chronic kidney disease (ckd-ap) in adults undergoing hemodialysis (hd)
Dosage: SOLUTION;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9074213 | NOVARTIS | Compositions and methods for inhibiting expression of a target gene |
Mar, 2022
(2 years ago) | |
US8546143 | NOVARTIS | Compositions and methods for inhibiting expression of a target gene |
Apr, 2022
(1 year, 11 months ago) | |
US8232383 | NOVARTIS | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
Feb, 2023
(1 year, 1 month ago) | |
US11078485 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Nov, 2023
(4 months ago) | |
US9708610 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Jan, 2024
(2 months ago) | |
US10669544 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(17 days ago) | |
US9708615 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(17 days ago) | |
US10273477 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(17 days ago) | |
US11530408 | NOVARTIS | Therapeutic compositions |
May, 2024
(a month from now) | |
US8809292 | NOVARTIS | Compositions and methods for inhibiting expression of the PCSK9 gene |
May, 2027
(3 years from now) | |
US10131907 | NOVARTIS | Glycoconjugates of RNA interference agents |
Aug, 2028
(4 years from now) | |
US8828956 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
US10806791 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
US9370582 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
US8106022 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(5 years from now) | |
US10125369 | NOVARTIS | PCSK9 iRNA compositions and methods of use thereof |
Aug, 2034
(10 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10590418 | NOVARTIS | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
Jul, 2022
(1 year, 8 months ago) | |
US10266825 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Nov, 2023
(4 months ago) | |
US8222222 | NOVARTIS | Compositions and methods for inhibiting expression of the PCSK9 gene |
Dec, 2027
(3 years from now) | |
US10851377 | NOVARTIS | Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder |
Aug, 2036
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 22, 2026 |
Drugs and Companies using INCLISIRAN SODIUM ingredient
NCE-1 date: 2025-12-22
Market Authorisation Date: 22 December, 2021
Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascv...
Dosage: SOLUTION;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11260053 | MIRUM | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
May, 2031
(7 years from now) | |
US11376251 | MIRUM | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
Oct, 2032
(8 years from now) | |
US11497745 | MIRUM | NA |
Feb, 2040
(15 years from now) | |
US11229647 | MIRUM | Methods for treating cholestasis |
Feb, 2040
(15 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 29, 2026 |
Orphan Drug Exclusivity (ODE) | Sep 29, 2028 |
New Patient Population (NPP) | Mar 13, 2026 |
Drugs and Companies using MARALIXIBAT CHLORIDE ingredient
NCE-1 date: 2025-09-29
Market Authorisation Date: 29 September, 2021
Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs)
Dosage: SOLUTION;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11684632 | TAKEDA PHARMS USA | Maribavir isomers, compositions, methods of making and methods of using |
Jan, 2032
(7 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 23, 2026 |
Orphan Drug Exclusivity (ODE) | Nov 23, 2028 |
Drugs and Companies using MARIBAVIR ingredient
NCE-1 date: 2025-11-23
Market Authorisation Date: 23 November, 2021
Treatment: Treatment of patients with post-transplant cytomegalovirus (cmv) infection/disease refractory to treatment with ganciclovir, valganciclovir, cidofovir, or foscarnet, where the patient is a stem cell, ...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10519146 | AMGEN INC | KRAS G12C inhibitors and methods of using the same |
May, 2038
(14 years from now) | |
US11236091 | AMGEN INC | Solid state forms |
May, 2040
(16 years from now) | |
US11827635 | AMGEN INC | Solid state forms |
May, 2040
(16 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11426404 | AMGEN INC | Dosing of KRAS inhibitor for treatment of cancers |
Sep, 2040
(16 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 28, 2026 |
Orphan Drug Exclusivity (ODE) | May 28, 2028 |
Drugs and Companies using SOTORASIB ingredient
NCE-1 date: 2025-05-28
Market Authorisation Date: 28 May, 2021
Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda-approved test, who have received at least one prior system...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7332472 | AURINIA | Cyclosporine analogue mixtures and their use as immunomodulating agents |
Oct, 2024
(6 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11622991 | AURINIA | Protocol for treatment of lupus nephritis |
Dec, 2037
(13 years from now) | |
US10286036 | AURINIA | Protocol for treatment of lupus nephritis |
Dec, 2037
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 22, 2026 |
Drugs and Companies using VOCLOSPORIN ingredient
NCE-1 date: 2025-01-22
Market Authorisation Date: 22 January, 2021
Treatment: Treatment of patients with active lupus nephritis
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7262298 | ALKERMES INC | 4-hydroxybenzomorphans |
Nov, 2025
(1 year, 7 months from now) | |
US9119848 | ALKERMES INC | Morphinan derivatives for the treatment of drug overdose |
Aug, 2031
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11351166 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
US11185541 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
US9126977 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
US10716785 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
US9517235 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
US11793805 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
US10300054 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
US11241425 | ALKERMES INC | Composition for treating mental illness |
Aug, 2031
(7 years from now) | |
US8778960 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Feb, 2032
(7 years from now) | |
US11707466 | ALKERMES INC | Immediate release multilayer tablet |
Nov, 2041
(17 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 28, 2026 |
Drugs and Companies using OLANZAPINE; SAMIDORPHAN L-MALATE ingredient
NCE-1 date: 2025-05-28
Market Authorisation Date: 28 May, 2021
Treatment: Method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan; Method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and ...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7732430 | MAYNE PHARMA | Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception |
Mar, 2025
(11 months from now) | |
US11793760 | MAYNE PHARMA | Orodispersible dosage unit containing an estetrol component |
Jun, 2036
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 15, 2026 |
Drugs and Companies using DROSPIRENONE; ESTETROL ingredient
NCE-1 date: 2025-04-15
Market Authorisation Date: 15 April, 2021
Treatment: Use by females of reproductive potential to prevent pregnancy
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7504095 | SENTYNL THERAPS INC | Method for obtaining precursor Z and use thereof for the production of a means for therapy of human molybdenum cofactor deficiency |
Jan, 2025
(10 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Feb 26, 2028 |
New Chemical Entity Exclusivity (NCE) | Feb 26, 2026 |
M (M) | Oct 27, 2025 |
Drugs and Companies using FOSDENOPTERIN HYDROBROMIDE ingredient
NCE-1 date: 2025-02-26
Market Authorisation Date: 26 February, 2021
Treatment: Method of treating molybdenum cofactor deficiency type a
Dosage: POWDER;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6992207 | ONCOPEPTIDES AB | Melphalan derivatives and their use as cancer chemotherapeutic drugs |
Jun, 2024
(2 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10285946 | ONCOPEPTIDES AB | Lyophilized preparations of melphalan flufenamide |
Apr, 2032
(8 years from now) | |
US11344622 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(8 years from now) | |
US10543274 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(8 years from now) | |
US10322182 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(8 years from now) | |
US10869928 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(8 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Feb 26, 2028 |
New Chemical Entity Exclusivity (NCE) | Feb 26, 2026 |
Drugs and Companies using MELPHALAN FLUFENAMIDE HYDROCHLORIDE ingredient
NCE-1 date: 2025-02-26
Market Authorisation Date: 26 February, 2021
Treatment: In combination with dexamethasone to treat relapsed or refactory multiple myeloma (refactory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-cd38 mab) in adults who received a...
Dosage: POWDER;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
USRE43728 | JANSSEN PHARMS | Thiazolidin-4-one derivatives |
Nov, 2024
(7 months from now) | |
US9062014 | JANSSEN PHARMS | Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one |
May, 2032
(8 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9000018 | JANSSEN PHARMS | Thiazolidin-4-one-derivatives |
Nov, 2024
(7 months from now) | |
US8273779 | JANSSEN PHARMS | Thiazolidin 4-one derivatives |
Dec, 2025
(1 year, 8 months from now) | |
US10220023 | JANSSEN PHARMS | Dosing regimen for a selective S1P1 receptor agonist |
Dec, 2035
(11 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 18, 2026 |
Drugs and Companies using PONESIMOD ingredient
NCE-1 date: 2025-03-18
Market Authorisation Date: 18 March, 2021
Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive dise...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8487129 | PROGENICS PHARMS INC | Heterodimers of glutamic acid |
Nov, 2027
(3 years from now) | |
US9861713 | PROGENICS PHARMS INC | PSMA-binding agents and uses thereof |
Jul, 2029
(5 years from now) | |
US8778305 | PROGENICS PHARMS INC | PSMA-binding agents and uses thereof |
Sep, 2030
(6 years from now) | |
US10947197 | PROGENICS PHARMS INC | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL |
Jun, 2037
(13 years from now) | |
US11851407 | PROGENICS PHARMS INC | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPYL |
Jun, 2037
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 26, 2026 |
Drugs and Companies using PIFLUFOLASTAT F-18 ingredient
NCE-1 date: 2025-05-26
Market Authorisation Date: 26 May, 2021
Treatment: Method of positron emission tomography (pet) in men with prostate cancer
Dosage: SOLUTION;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11458143 | SUPERNUS PHARMS | NA |
Sep, 2029
(5 years from now) | |
US11324753 | SUPERNUS PHARMS | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
Sep, 2029
(5 years from now) | |
US9662338 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(8 years from now) | |
US9358204 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(8 years from now) | |
US9603853 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(8 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 2, 2026 |
New Patient Population (NPP) | Apr 29, 2025 |
Drugs and Companies using VILOXAZINE HYDROCHLORIDE ingredient
NCE-1 date: 2025-04-02
Market Authorisation Date: 02 April, 2021
Treatment: U-727: for the treatment of attention deficit hyperactivity disorder (adhd); For the treatment of attention deficit hyperactivity disorder (adhd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9499545 | ABBVIE INC | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(7 years from now) | |
US8754096 | ABBVIE INC | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(8 years from now) | |
US9850246 | ABBVIE INC | Process for making CGRP receptor antagonists |
Mar, 2033
(8 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10117836 | ABBVIE INC | Tablet formulation for CGRP active compounds |
Jan, 2035
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication (I) | Apr 17, 2026 |
New Chemical Entity Exclusivity (NCE) | Sep 28, 2026 |
Drugs and Companies using ATOGEPANT ingredient
NCE-1 date: 2025-09-28
Market Authorisation Date: 28 September, 2021
Treatment: Preventive treatment of episodic migraine in adults
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8357693 | KADMON PHARMS LLC | Pharmacokinetically improved compounds |
Oct, 2029
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9815820 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(9 years from now) | |
US10696660 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(9 years from now) | |
US10183931 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(9 years from now) | |
US11311541 | KADMON PHARMS LLC | Treatment of GVHD |
Apr, 2035
(11 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 16, 2026 |
Orphan Drug Exclusivity (ODE) | Jul 16, 2028 |
Drugs and Companies using BELUMOSUDIL MESYLATE ingredient
NCE-1 date: 2025-07-16
Market Authorisation Date: 16 July, 2021
Treatment: For the treatment of chronic graft versus hold disease; For the treatment of chronic graft versus host disease; Treatment of adults and pediatric patients 12 and older with sclerodermatous form of chr...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8829195 | NOVARTIS | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
May, 2033
(9 years from now) | |
US11407735 | NOVARTIS | Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide |
May, 2040
(16 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Oct 29, 2026 |
Orphan Drug Exclusivity (ODE) | Oct 29, 2028 |
Drugs and Companies using ASCIMINIB HYDROCHLORIDE ingredient
NCE-1 date: 2025-10-29
Market Authorisation Date: 29 October, 2021
Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml)
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9169307 | APELLIS PHARMS | Potent compstatin analogs |
Nov, 2027
(3 years from now) | |
US7989589 | APELLIS PHARMS | Compstatin analogs with improved activity |
Dec, 2027
(3 years from now) | |
US7888323 | APELLIS PHARMS | Potent compstatin analogs |
Dec, 2027
(3 years from now) | |
US11661441 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Jan, 2033
(8 years from now) | |
US10125171 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Aug, 2033
(9 years from now) | |
US10035822 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
US10875893 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
US11292815 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9056076 | APELLIS PHARMS | Method of treating age-related macular degeneration comprising administering a compstatin analog |
Oct, 2026
(2 years from now) | |
US8168584 | APELLIS PHARMS | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
Apr, 2027
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product (NP) | Feb 22, 2026 |
New Chemical Entity Exclusivity (NCE) | May 14, 2026 |
Drugs and Companies using PEGCETACOPLAN ingredient
NCE-1 date: 2025-05-14
Market Authorisation Date: 17 February, 2023
Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by intravitreal administration of pegcetacoplan; Treatment of geographic atrophy secondary to age-related macular degenera...
Dosage: SOLUTION;INTRAVITREAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8906938 | CHEMOCENTRYX | C5aR antagonists |
Dec, 2029
(5 years from now) | |
US8445515 | CHEMOCENTRYX | C5aR antagonists |
Feb, 2031
(6 years from now) | |
US11603356 | CHEMOCENTRYX | Amorphous form of a complement component C5a receptor |
May, 2041
(17 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Oct 7, 2028 |
New Chemical Entity Exclusivity (NCE) | Oct 7, 2026 |
Drugs and Companies using AVACOPAN ingredient
NCE-1 date: 2025-10-07
Market Authorisation Date: 07 October, 2021
Treatment: An adjunctive treatment of adult patients with tavneos (avacopan) with severe active anca-associated vasculitis (gpa and mpa) in combination with standard therapy including glucocorticoids
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8921357 | EMD SERONO INC | Pyridazinone derivatives |
May, 2028
(4 years from now) | |
US8329692 | EMD SERONO INC | Pyrimidinyl pyridazinone derivatives |
Oct, 2029
(5 years from now) | |
US8580781 | EMD SERONO INC | Pyridazinone derivatives |
Mar, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9284300 | EMD SERONO INC | Pyridazinone derivatives |
Apr, 2028
(4 years from now) | |
US9403799 | EMD SERONO INC | Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase |
Jul, 2028
(4 years from now) | |
US9062029 | EMD SERONO INC | Pyrimidinyl pyridazinone derivatives |
Jul, 2028
(4 years from now) | |
US8658643 | EMD SERONO INC | Pyrimidinyl pyridazinone derivatives |
Jul, 2028
(4 years from now) | |
US8927540 | EMD SERONO INC | Pyridazinone derivatives |
Jul, 2028
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 3, 2026 |
Orphan Drug Exclusivity (ODE) | Feb 3, 2028 |
Drugs and Companies using TEPOTINIB HYDROCHLORIDE ingredient
NCE-1 date: 2025-02-03
Market Authorisation Date: 03 February, 2021
Treatment: Treating a solid tumor, including lung cancer, with a met alteration(s), or stabilizing or improving symptoms associated with having a solid tumor, including lung cancer, with a met alteration(s), by ...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9067896 | HELSINN HLTHCARE | Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl) -phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof |
Aug, 2028
(4 years from now) | |
US8552002 | HELSINN HLTHCARE | Compounds and compositions as protein kinase inhibitors |
Aug, 2029
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10278969 | HELSINN HLTHCARE | Pharmaceutical dosage forms |
Dec, 2034
(10 years from now) | |
US11160804 | HELSINN HLTHCARE | Pharmaceutical dosage forms |
Dec, 2034
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 28, 2026 |
Orphan Drug Exclusivity (ODE) | May 28, 2028 |
Drugs and Companies using INFIGRATINIB PHOSPHATE ingredient
NCE-1 date: 2025-05-28
Market Authorisation Date: 28 May, 2021
Treatment: NA
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10570142 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(9 years from now) | |
US9150579 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(9 years from now) | |
US9969740 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(11 years from now) | |
US10414773 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(11 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10981919 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(9 years from now) | |
US10072013 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(9 years from now) | |
US9669033 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(9 years from now) | |
US10947244 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(11 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 5, 2026 |
Drugs and Companies using UMBRALISIB TOSYLATE ingredient
NCE-1 date: 2025-02-05
Market Authorisation Date: 05 February, 2021
Treatment: Relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen; Relapsed or refractory follicular lymphoma (fl) who have received at least three prior...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10736896 | MERCK SHARP DOHME | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(7 years from now) | |
US8420656 | MERCK SHARP DOHME | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(7 years from now) | |
US9604948 | MERCK SHARP DOHME | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines |
Nov, 2032
(8 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11439642 | MERCK SHARP DOHME | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(7 years from now) | |
US9993476 | MERCK SHARP DOHME | Substituted 5-flouro-1H-pyrazolopyridines and their use |
May, 2031
(7 years from now) | |
US8921377 | MERCK SHARP DOHME | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(7 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 19, 2026 |
Drugs and Companies using VERICIGUAT ingredient
NCE-1 date: 2025-01-19
Market Authorisation Date: 19 January, 2021
Treatment: Reducing the risk of cardiovascular death and heart failure (hf) hospitalization following a hospitalization for hf or need for outpatient iv diuretics, in adults with symptomatic chronic hf and eject...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8410103 | VIIV HLTHCARE | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
Apr, 2026
(2 years from now) | |
US10927129 | VIIV HLTHCARE | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
Apr, 2026
(2 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 21, 2026 |
New Patient Population (NPP) | Mar 29, 2025 |
M (M) | Jan 31, 2025 |
Drugs and Companies using CABOTEGRAVIR SODIUM ingredient
NCE-1 date: 2025-01-21
Market Authorisation Date: 21 January, 2021
Treatment: Treatment of hiv-1 in an adult in combination with rilpivirine
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8198242 | BIOMARIN PHARM | Variants of C-type natriuretic peptide |
Jun, 2030
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE48267 | BIOMARIN PHARM | Variants of C-type natriuretic peptide |
May, 2030
(6 years from now) | |
US9907834 | BIOMARIN PHARM | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Aug, 2036
(12 years from now) | |
US10646550 | BIOMARIN PHARM | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Aug, 2036
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 19, 2026 |
Orphan Drug Exclusivity (ODE) | Nov 19, 2028 |
New Patient Population (NPP) | Oct 20, 2026 |
Drugs and Companies using VOSORITIDE ingredient
NCE-1 date: 2025-11-19
Market Authorisation Date: 19 November, 2021
Treatment: Use to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses
Dosage: POWDER;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9969689 | MERCK SHARP DOHME | Aryl ethers and uses thereof |
Sep, 2034
(10 years from now) | |
US9908845 | MERCK SHARP DOHME | Aryl ethers and uses thereof |
Sep, 2034
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Aug 13, 2026 |
New Indication (I) | Dec 14, 2026 |
Orphan Drug Exclusivity (ODE) | Aug 13, 2028 |
Drugs and Companies using BELZUTIFAN ingredient
NCE-1 date: 2025-08-13
Market Authorisation Date: 13 August, 2021
Treatment: Treatment of adult patients with von hippel-lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not r...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10442847 | ZEALAND PHARMA | Glucagon analogues |
Feb, 2035
(10 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11795204 | ZEALAND PHARMA | Glucagon analogues |
Jan, 2034
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 22, 2026 |
Drugs and Companies using DASIGLUCAGON HYDROCHLORIDE ingredient
NCE-1 date: 2025-03-22
Market Authorisation Date: 22 March, 2021
Treatment: Method of treating diabetic hypoglycemia
Dosage: SOLUTION;SUBCUTANEOUS